Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Connie Hess

Concepts (264)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Peripheral Arterial Disease
50
2026
503
11.650
 Why?
Lower Extremity
26
2026
438
4.460
 Why?
Percutaneous Coronary Intervention
22
2021
543
4.190
 Why?
Coronary Artery Disease
17
2024
741
4.180
 Why?
Platelet Aggregation Inhibitors
30
2026
497
3.620
 Why?
Myocardial Infarction
19
2026
1209
3.610
 Why?
Fibrinolytic Agents
13
2025
291
3.300
 Why?
Endovascular Procedures
9
2026
384
2.750
 Why?
Radial Artery
9
2019
70
2.500
 Why?
Purinergic P2Y Receptor Antagonists
8
2018
69
2.250
 Why?
Rivaroxaban
16
2026
267
2.200
 Why?
Aspirin
16
2026
399
2.130
 Why?
Vascular Surgical Procedures
8
2026
339
2.120
 Why?
Acute Coronary Syndrome
7
2023
293
2.100
 Why?
Ischemia
9
2023
421
1.640
 Why?
Femoral Artery
9
2024
190
1.620
 Why?
Stroke
11
2026
1256
1.440
 Why?
Anticoagulants
11
2026
722
1.350
 Why?
Hemorrhage
18
2026
809
1.350
 Why?
Treatment Outcome
43
2026
11679
1.330
 Why?
Drug-Eluting Stents
4
2021
88
1.290
 Why?
Anticholesteremic Agents
3
2023
152
1.240
 Why?
Hypercholesterolemia
2
2022
92
1.200
 Why?
Atherosclerosis
6
2024
409
1.200
 Why?
Factor Xa Inhibitors
8
2026
187
1.190
 Why?
Cholesterol, LDL
5
2024
358
1.180
 Why?
Postoperative Complications
6
2021
2919
1.150
 Why?
Coronary Vessel Anomalies
5
2026
38
1.110
 Why?
Venous Thromboembolism
2
2023
324
1.110
 Why?
Patient Readmission
4
2021
758
1.110
 Why?
Cardiovascular Diseases
7
2024
2168
0.980
 Why?
Aged
46
2026
25913
0.960
 Why?
Disease Management
4
2021
645
0.950
 Why?
Humans
105
2026
144759
0.940
 Why?
Ticlopidine
3
2016
54
0.930
 Why?
Vascular Diseases
5
2026
251
0.930
 Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
5
2024
439
0.900
 Why?
Risk Factors
31
2026
10779
0.870
 Why?
Atrial Fibrillation
4
2017
550
0.870
 Why?
Saphenous Vein
2
2015
37
0.870
 Why?
Graft Occlusion, Vascular
2
2015
42
0.870
 Why?
Learning Curve
2
2015
70
0.820
 Why?
Cardiac Catheterization
3
2018
560
0.810
 Why?
Middle Aged
44
2026
35875
0.810
 Why?
Female
60
2026
78271
0.790
 Why?
Thrombosis
4
2024
393
0.790
 Why?
Fibrin Fibrinogen Degradation Products
1
2023
93
0.760
 Why?
Male
53
2026
72315
0.760
 Why?
Warfarin
2
2015
170
0.760
 Why?
Coronary Artery Bypass
2
2015
268
0.750
 Why?
Pyridones
2
2015
199
0.750
 Why?
Coronary Vessels
4
2024
251
0.740
 Why?
Antifibrinolytic Agents
1
2023
62
0.740
 Why?
Postoperative Hemorrhage
2
2013
104
0.720
 Why?
Sex Characteristics
3
2023
790
0.710
 Why?
Brain Ischemia
2
2022
358
0.700
 Why?
Registries
15
2026
2385
0.680
 Why?
Diabetes Complications
2
2021
222
0.680
 Why?
Paclitaxel
2
2021
255
0.680
 Why?
Gout
2
2018
35
0.670
 Why?
Blood Coagulation Disorders
1
2023
189
0.670
 Why?
Heparin
3
2023
244
0.670
 Why?
Hypolipidemic Agents
1
2021
88
0.660
 Why?
Pyrazoles
2
2015
509
0.640
 Why?
Angina Pectoris
2
2017
75
0.630
 Why?
Drug Therapy, Combination
12
2026
1047
0.620
 Why?
Dyslipidemias
1
2021
181
0.600
 Why?
Leg
1
2021
239
0.590
 Why?
Risk Assessment
12
2026
3671
0.570
 Why?
Myocardial Revascularization
2
2016
85
0.560
 Why?
Coronary Angiography
4
2024
323
0.560
 Why?
Reperfusion
1
2018
54
0.560
 Why?
Patient Care Team
1
2024
689
0.560
 Why?
Time Factors
15
2026
7173
0.550
 Why?
Upper Extremity
1
2018
112
0.510
 Why?
American Heart Association
5
2024
350
0.490
 Why?
Databases, Factual
2
2021
1486
0.470
 Why?
Societies, Medical
3
2024
887
0.450
 Why?
Recurrence
6
2026
1135
0.450
 Why?
Quality Indicators, Health Care
3
2023
335
0.440
 Why?
Medicare
4
2021
886
0.430
 Why?
Acute Disease
4
2021
1030
0.430
 Why?
Popliteal Artery
4
2024
62
0.430
 Why?
United States
24
2026
15966
0.420
 Why?
Coronary Disease
1
2017
383
0.420
 Why?
Intermittent Claudication
3
2024
121
0.420
 Why?
Secondary Prevention
3
2026
254
0.410
 Why?
Randomized Controlled Trials as Topic
3
2024
1720
0.410
 Why?
Hospitals
3
2017
730
0.400
 Why?
Cardiology
4
2024
353
0.400
 Why?
Sex Factors
8
2026
2112
0.400
 Why?
Office Visits
1
2013
90
0.390
 Why?
Follow-Up Studies
6
2021
5408
0.390
 Why?
Hematoma
2
2022
59
0.350
 Why?
Aftercare
1
2013
223
0.350
 Why?
Subclavian Vein
1
2011
15
0.340
 Why?
Subclavian Artery
1
2011
28
0.340
 Why?
Thrombocytopenia
1
2012
205
0.330
 Why?
Arteriovenous Fistula
1
2011
38
0.330
 Why?
Comorbidity
5
2024
1658
0.330
 Why?
Health Status Disparities
1
2014
321
0.320
 Why?
Catheterization
1
2011
183
0.320
 Why?
Electric Countershock
1
2011
127
0.320
 Why?
Referral and Consultation
1
2016
851
0.300
 Why?
Quality of Life
3
2022
3185
0.300
 Why?
Adenosine Diphosphate
1
2009
84
0.300
 Why?
Proportional Hazards Models
4
2021
1325
0.290
 Why?
Nitric Oxide Synthase Type III
1
2009
204
0.280
 Why?
Cardiovascular Agents
2
2022
164
0.280
 Why?
Gene Expression Regulation, Enzymologic
1
2009
269
0.280
 Why?
Double-Blind Method
5
2026
2029
0.280
 Why?
AMP-Activated Protein Kinases
1
2009
190
0.270
 Why?
Prospective Studies
8
2024
7990
0.270
 Why?
Retrospective Studies
9
2024
17066
0.260
 Why?
Vascular System Injuries
2
2019
77
0.260
 Why?
Peptides
1
2013
995
0.260
 Why?
Defibrillators, Implantable
1
2011
382
0.260
 Why?
Cardiomyopathies
1
2011
338
0.260
 Why?
Catheterization, Peripheral
2
2019
118
0.250
 Why?
Healthcare Disparities
1
2014
727
0.250
 Why?
Aged, 80 and over
8
2026
8265
0.240
 Why?
Cause of Death
3
2018
471
0.240
 Why?
Pregnancy Complications, Cardiovascular
1
2026
83
0.230
 Why?
Ankle Brachial Index
2
2022
41
0.220
 Why?
Limb Salvage
2
2026
70
0.220
 Why?
Kaplan-Meier Estimate
3
2021
965
0.210
 Why?
Practice Guidelines as Topic
3
2017
1560
0.200
 Why?
Arteries
2
2022
259
0.200
 Why?
Age Factors
4
2016
3333
0.200
 Why?
Patient Discharge
3
2021
983
0.200
 Why?
Thromboplastin
1
2023
69
0.200
 Why?
Endothelial Cells
1
2009
869
0.190
 Why?
Neoplasms
2
2017
2875
0.190
 Why?
Incidence
5
2021
2879
0.190
 Why?
Migraine Disorders
1
2024
112
0.180
 Why?
Myocardial Ischemia
2
2015
285
0.180
 Why?
Longitudinal Studies
5
2018
2947
0.180
 Why?
Numbers Needed To Treat
1
2021
7
0.180
 Why?
Ulcer
1
2021
37
0.180
 Why?
Odds Ratio
2
2022
1075
0.170
 Why?
Lactones
1
2022
58
0.170
 Why?
Exercise Therapy
2
2026
473
0.170
 Why?
Walking
2
2022
545
0.160
 Why?
Syndrome
1
2021
380
0.160
 Why?
Angioplasty, Balloon
1
2021
94
0.160
 Why?
Cohort Studies
3
2026
5960
0.160
 Why?
Cholesterol
1
2022
406
0.160
 Why?
Antineoplastic Agents, Phytogenic
1
2021
177
0.160
 Why?
Clinical Trials as Topic
2
2017
1053
0.160
 Why?
Pharmaceutical Preparations
1
2021
170
0.150
 Why?
Hypertension
2
2022
1263
0.150
 Why?
United Kingdom
1
2020
338
0.150
 Why?
Extremities
1
2020
140
0.150
 Why?
Patient Education as Topic
1
2024
780
0.150
 Why?
Receptors, Purinergic P2Y12
1
2018
7
0.140
 Why?
Platelet Glycoprotein GPIIb-IIIa Complex
1
2018
26
0.140
 Why?
Aorta
1
2021
429
0.140
 Why?
Hospitalization
2
2019
2433
0.140
 Why?
Logistic Models
2
2026
2117
0.140
 Why?
Antithrombins
1
2018
70
0.130
 Why?
Non-ST Elevated Myocardial Infarction
1
2017
25
0.130
 Why?
Stents
3
2020
556
0.130
 Why?
Pyridines
1
2022
605
0.130
 Why?
Plaque, Atherosclerotic
1
2017
60
0.130
 Why?
ST Elevation Myocardial Infarction
1
2017
63
0.130
 Why?
Intraoperative Complications
1
2017
155
0.120
 Why?
Diabetes Mellitus, Type 2
2
2024
2583
0.120
 Why?
Uric Acid
1
2017
166
0.120
 Why?
Mortality
1
2018
375
0.120
 Why?
Stress Disorders, Post-Traumatic
1
2024
893
0.120
 Why?
Consensus
1
2017
488
0.110
 Why?
North Carolina
1
2015
128
0.110
 Why?
Hospital Bed Capacity
1
2014
28
0.110
 Why?
Blood Platelets
1
2018
400
0.110
 Why?
Hospitals, Low-Volume
1
2014
25
0.110
 Why?
Smoking
1
2022
1472
0.110
 Why?
Antibodies, Monoclonal
2
2023
1519
0.110
 Why?
Clinical Trials Data Monitoring Committees
1
2014
3
0.110
 Why?
Hospitals, High-Volume
1
2014
49
0.110
 Why?
Heart Failure
3
2026
2323
0.110
 Why?
Vascular Patency
1
2014
121
0.100
 Why?
Diagnosis-Related Groups
1
2013
35
0.100
 Why?
Prosthesis Design
2
2017
357
0.100
 Why?
Professional Competence
1
2014
98
0.100
 Why?
Diabetes Mellitus
1
2022
1098
0.100
 Why?
Survivors
1
2017
520
0.100
 Why?
Fee-for-Service Plans
1
2013
98
0.100
 Why?
Guideline Adherence
1
2017
589
0.090
 Why?
Platelet Factor 4
1
2012
36
0.090
 Why?
Infusions, Intravenous
1
2013
423
0.090
 Why?
Practice Patterns, Physicians'
2
2018
1356
0.090
 Why?
Inflammation
1
2023
2878
0.090
 Why?
Antibodies, Monoclonal, Humanized
1
2017
985
0.090
 Why?
Smoking Cessation
2
2026
439
0.080
 Why?
Prognosis
2
2021
4282
0.080
 Why?
Naphthalimides
1
2009
2
0.080
 Why?
Calcium-Calmodulin-Dependent Protein Kinase Kinase
1
2009
4
0.080
 Why?
Prevalence
3
2024
2834
0.080
 Why?
Heart Diseases
1
2013
349
0.080
 Why?
Radiography, Interventional
1
2011
130
0.080
 Why?
Reoperation
2
2024
630
0.080
 Why?
Hospital Mortality
1
2014
1030
0.070
 Why?
Predictive Value of Tests
1
2014
2115
0.070
 Why?
Multivariate Analysis
2
2026
1539
0.070
 Why?
Sensitivity and Specificity
1
2013
1985
0.070
 Why?
Benzimidazoles
1
2009
190
0.070
 Why?
Protein Isoforms
1
2009
402
0.070
 Why?
Enzyme Activation
1
2009
766
0.070
 Why?
Combined Modality Therapy
2
2021
1266
0.070
 Why?
Communication
1
2014
965
0.070
 Why?
Case-Control Studies
1
2015
3604
0.070
 Why?
Phosphatidylinositol 3-Kinases
1
2009
380
0.060
 Why?
Cattle
1
2009
1000
0.060
 Why?
Quality Improvement
1
2014
1289
0.060
 Why?
Clinical Competence
1
2014
1244
0.060
 Why?
Phosphorylation
1
2009
1732
0.060
 Why?
Adult
3
2026
40449
0.050
 Why?
Autoantibodies
1
2012
1501
0.050
 Why?
Cell Movement
1
2009
965
0.050
 Why?
Fibromuscular Dysplasia
1
2024
8
0.050
 Why?
Young Adult
1
2021
14105
0.050
 Why?
Atherectomy
1
2024
37
0.050
 Why?
Subtilisin
1
2023
4
0.050
 Why?
Proprotein Convertases
1
2023
16
0.050
 Why?
Angiography
1
2024
208
0.050
 Why?
Arrhythmias, Cardiac
1
2026
361
0.050
 Why?
Lipoprotein(a)
1
2023
68
0.050
 Why?
Proprotein Convertase 9
1
2023
87
0.050
 Why?
Disability Evaluation
1
2024
310
0.050
 Why?
Pregnancy
2
2026
7190
0.040
 Why?
Mobility Limitation
1
2022
66
0.040
 Why?
Adolescent
1
2021
22428
0.040
 Why?
Coated Materials, Biocompatible
1
2021
65
0.040
 Why?
Public Health Surveillance
1
2021
83
0.040
 Why?
Diagnostic Tests, Routine
1
2021
108
0.040
 Why?
Internationality
1
2020
156
0.040
 Why?
Length of Stay
1
2026
1337
0.040
 Why?
Disease Susceptibility
1
2021
348
0.040
 Why?
Punctures
1
2019
40
0.040
 Why?
Advisory Committees
1
2021
228
0.040
 Why?
Chronic Disease
1
2025
1813
0.040
 Why?
Global Health
1
2021
401
0.030
 Why?
Drug Utilization Review
1
2017
61
0.030
 Why?
Health Care Costs
1
2021
427
0.030
 Why?
Dose-Response Relationship, Drug
1
2021
2027
0.030
 Why?
Socioeconomic Factors
1
2021
1326
0.030
 Why?
Surgery, Computer-Assisted
1
2017
84
0.030
 Why?
Comparative Effectiveness Research
1
2017
170
0.030
 Why?
Chi-Square Distribution
1
2017
529
0.030
 Why?
Signal Transduction
1
2009
5226
0.030
 Why?
Genetic Predisposition to Disease
1
2024
2363
0.030
 Why?
Platelet Function Tests
1
2015
34
0.030
 Why?
Drug Prescriptions
1
2017
284
0.030
 Why?
Patient Selection
1
2019
719
0.030
 Why?
Administration, Oral
1
2017
847
0.030
 Why?
Early Termination of Clinical Trials
1
2014
18
0.030
 Why?
Hypoglycemic Agents
1
2024
1387
0.030
 Why?
Depression
1
2024
1558
0.030
 Why?
Retreatment
1
2013
77
0.020
 Why?
Canada
1
2014
428
0.020
 Why?
Mass Screening
1
2021
1347
0.020
 Why?
Linear Models
1
2014
854
0.020
 Why?
Patient Preference
1
2014
224
0.020
 Why?
Animals
1
2009
38058
0.020
 Why?
Hess's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (264) concept(s)
_
Co-Authors Expand Description
See all (16) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)